Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01949662 · ClinicalTrials.gov registry record · Phase 2
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
A Phase 2 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT01949662: Active Phase 2 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
NCT01949662 is a Phase 2 study of Advanced Cancers that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 93 participants, above the 61-participant average among 10 other Advanced Cancers trials with a reported enrollment target (52% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01949662, a Phase 2 study of Advanced Cancers, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.
Primary Outcome
The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient.
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Questionnaires
- DRUG Lorazepam
- DRUG Haloperidol decanoate
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-01 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 2 |
What the registry record for NCT01949662 still lists
NCT01949662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, above the 61-participant average among 10 other Advanced Cancers trials with a reported enrollment target (52% higher).
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01949662 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01949662 about?
NCT01949662 is a clinical study titled "Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer". This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with ...
What is the current status of trial NCT01949662?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2014-01. Estimated completion is 2028-01-01.
What conditions does trial NCT01949662 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT01949662?
The interventions under investigation include: Placebo (DRUG), Questionnaires (BEHAVIORAL), Lorazepam (DRUG), Haloperidol decanoate (DRUG).
Who is sponsoring clinical trial NCT01949662?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01949662 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01949662's enrollment target sits among peer trials
93 3rd of 10 higher than 8 of 10 other Advanced Cancers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
The Effects of Thalidomide on Symptom Clusters
COMPLETED · Phase 2
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Study of Vemurafenib, Carboplatin, and Paclitaxel
COMPLETED · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia